Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Gastroenterol Hepatol ; 28(12): 1468-1472, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27541710

RESUMEN

AIM: The aim of this study was to determine demographic and clinical features in children diagnosed with gallstones, risk factors for gallstone formation, the effectiveness of ursodeoxycholic acid therapy, and the course of the disease. MATERIALS AND METHODS: Patients aged 0-18 years were followed up for at least 6 months after the diagnosis of gallstones with ultrasonography and were evaluated retrospectively. Patients were evaluated with respect to age, sex, presenting symptoms, BMI, facilitating factors, accompanying diseases, family history of gallstones, history of ceftriaxone use, laboratory tests, ultrasonography findings and follow-up, and therapeutic approaches and results. RESULTS: The study was completed with 70 patients. Thirty-nine (55.7%) patients were females. The mean age of the patients was 9.3±5.29 (0.3-18) years. The mean age among females was statistically significantly higher than that among males (P=0.007).No risk factor for stone formation was encountered in 50% of cases, whereas a family history of gallstones was present in 17.1%. Use of ceftriaxone was present in 8.6% of cases, total parenteral nutrition in 10%, obesity in 5.7%, hereditary spherocytosis in 4.3%, and Down's syndrome in 4.3%. The probability of dissolution of stones was 3.6 times higher in patients with stone sizes up to 5 mm [odds ratio (OR): 3.65, P=0.020], 3.9 times higher in those aged younger than 2 years (OR: 3.92, P=0.021), and 13.9 times higher in those with a single stone (OR: 13.97, P=0.003). CONCLUSION: Our findings show that unknown causes are still prevalent in stone formation and that ursodeoxycholic acid exerts no effect on stone dissolution; however, diagnosis at younger than 2 years of age, a single stone, and small size of stone are factors affecting dissolution.


Asunto(s)
Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Cálculos Biliares/epidemiología , Obesidad/epidemiología , Nutrición Parenteral Total/estadística & datos numéricos , Adolescente , Distribución por Edad , Niño , Preescolar , Colagogos y Coleréticos/uso terapéutico , Colecistectomía , Familia , Femenino , Estudios de Seguimiento , Cálculos Biliares/etiología , Cálculos Biliares/terapia , Humanos , Lactante , Masculino , Anamnesis , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Distribución por Sexo , Resultado del Tratamiento , Ácido Ursodesoxicólico/uso terapéutico
2.
Saudi Med J ; 36(9): 1046-52, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26318460

RESUMEN

OBJECTIVES: To investigate the protective effects of L-carnitine (LC) on lungs in an experimental obstructive jaundice (OJ) model. METHODS: This was conducted for 2 months between May 2011 and July 2011 at Suleyman Demirel University School of Medicine Experimental and Clinical Research Center, Isparta, Turkey. Thirty-eight Wistar-Albino rats with an average weight of 250-300 g were divided into 3 groups of control, OJ, and OJ + L-carnitine treatment (LCT). L-carnitine was injected intravenously into the tail vein at a dose of 50 mg/kg/day for 10 days to the LCT group. Animals were sacrificed 10 days later. Enzyme levels were measured in the lung tissue; malondialdehyde, myeloperoxidase (MPO), glutathione peroxidase (GSH-Px), catalase, and superoxide dismutase. Tumor necrosis factor-alfa, interleukin 6 (IL-6), IL-8, and C-reactive protein levels were studied in plasma samples. Histopathological changes in the lungs were examined.  RESULTS: There was a decreased in GSH-Px, MPO, and IL-8 levels (p less than 0.05) in the LCT group. The histopathological examination showed that neutrophil leukocyte infiltration and edema formation decreased and destruction of lung parenchyma disappeared following the treatment with LC (p less than 0.05).  CONCLUSION: L-carnitine has a protective effect against lung damage due to experimental obstructive jaundice, possibly by altering anticytokine and antioxidant activity, and by decreasing the neutrophil migration.


Asunto(s)
Lesión Pulmonar Aguda/tratamiento farmacológico , Carnitina/uso terapéutico , Colestasis/complicaciones , Lesión Pulmonar Aguda/sangre , Lesión Pulmonar Aguda/etiología , Lesión Pulmonar Aguda/patología , Animales , Colestasis/sangre , Colestasis/patología , Masculino , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA